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Abstract
Background: Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-
analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory
agents (NSAIDs) and triptans.
Methods: We conducted systematic searches in database PubMed and Embase. Treatment effectiveness was
compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area
(SUCRA) was created to rank those interventions.
Results: Eletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with
respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while
other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates
a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan.
Conclusion: This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive
point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component
medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.
Keywords: Migraine disorders, Triptans, Non-steroidal anti-inflammatory agents, Network meta-analysis
Background
Migraine is a neurological disorder resulting in large
socioeconomic burden affecting approximately 18% of
females and 6% of males in the United States [1]. The
prevalence of migraine varies with age, females between
35 and 45 years old exhibits the highest prevalence [2].
Apart from the factor of age, the prevalence of migraine
in the U.S. also varied with household income and race,
and such findings are consistent with studies carried out
in other countries [3, 4]. Headache is the primary symp-
tom of migraine and patients may also be afflicted by
other symptoms including pulsatile pain, light sensitivity,
sound sensitivity, nausea, unilateral pain, blurred vision
and emesis. Although a large number of treatments have
been developed for migraine over the past decades, sev-
eral disputes have been encountered by clinicians such
as misclassification of migraine, inappropriate selection
of treatment and medication overuse. Among them,
medication overuse has become a major issue in chronic
migraine patients who may eventually develop a disab-
ling condition called medication-overuse headache [5].
Therefore, awareness and understanding of migraine
should be improved and corresponding treatments or
medications should be further explored to overcome
these issues.
Two types of migraine therapies have been developed:
preventive therapies which are used to reduce attack fre-
quency or severity and acute therapies which are used for
the sake of aborting attacks. Compared to preventive ther-
apies, acute therapies are able to provide patients with
rapid and complete relief with minimal or no adverse
events and hence they are recommended for promptly
alleviating the symptoms of patients [6]. The selection of
acute treatments has been differentiated into two path-
ways: non-specific medications which include analgesics
and non-steroidal anti-inflammatory drugs (NSAIDs); and
specific medications which include ergot derivatives and
triptans [5]. As suggested by the European Federation of
Neurological Societies (EFNS), both oral NSAIDs and
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triptans are recommended for treating migraine attacks
[7]. Moreover, evidence from the American Headache
Society (AHS) concluded that the following treatments
are deemed to be effective acute therapies for migraine:
triptans, NSAIDs, ergotamine derivatives, opioids and
other combinational medications [8]. Stratified care is a
primary strategy often used in selecting medications for
migraine patients and this strategy takes several aspects
into account: attack severity, the presence of associated
symptoms and the degree of disability resulting from mi-
graine [9]. However, other factors such as dosage may also
have significant influence on the overall effectiveness of
medications that are used to abort migraine attacks.
Among the common acute treatments that are used
for aborting migraine, different levels of evidence have
been provided by a wide range of studies. Although the
efficacy of some medications have been established, this
does not imply that such medications should be consid-
ered as the first line treatments for migraine patients
since it may cause adverse events that are specifically
associated with these medications. Despite the growing
popularity of triptans, NSAIDs remain one of the most
recommended acute migraine treatments and they are
often used as an initial strategy for aborting migraine
attacks [9]. On the other hand, triptans are often used
as a rescue medication if an initial treatment fails to
abort migraine attacks and evidence suggests that about
60% of non-responders to NSAIDs can be treated by
triptans [10]. One distinctive advantage of triptans for
migraine patients is that they can be effective at any
time during a migraine attack and such an advantage
may reduce the impact of dosage timing on the overall
efficacy. Moreover, some evidence suggests that earlier
intervention by using triptans is associated with an en-
hanced efficacy [11, 12], while some randomized trials
do not support such an improved efficacy when pa-
tients experienced allodynia in the course of a migraine
attack [13, 14].
Despite the fact that both NSAIDs and triptans have
been recommended by the EFNS and AHS as acute
treatments for migraine, comparing NSAIDs with trip-
tans is a challenging task. Conventional meta-analysis
has several limitations due to the lack of evidence as well
as lack of indirect evidence.. For this reason, we de-
signed this network meta-analysis (NMA) to compares
the relative efficacy and tolerability between NSAIDs
and triptans. We hope that the approach of NMA can
provide comprehensive evidence with respect to the effi-
cacy and tolerability of these two popular medications.
Methods
Search strategy
We employed search strategies to explore the medical
literature for relevant studies in PubMed and EMBASE
systematically, and 2,967 records were identified using
the following terms: “migraine disorders”, “tryptans”,
“non-steroidal anti-inflammatory agents”, “ergot alka-
loids”, “opioid analgesics”, “sumatriptan”, “zolmitriptan”,
“almotriptan”, “rizatriptan”, “naratriptan”, “ibuprofen”,
“eletriptan”, “diclofenac-potassium” and “aspirin” in
PubMed. Reviewers also provided 3 additional references.
As flow chart Fig. 1 illustrates, among the total 2,970
records, 1,263 were identified as duplicates and hence
removed after assessment. 1,408 more studies were
excluded from the remaining 1,707 records according
to the exclusion criteria, leaving 299 remnant studies.
Full-text articles were viewed and included if they met
the inclusion criteria, or excluded if not. Eventually 88
studies were included in this research [12, 15–101].
Inclusion criteria
Articles were included if they: (1) were randomized clin-
ical trials (RCTs); (2) were categorized as double blind;
(3) included relevant clinical outcomes and treatments;
(4) contained comparisons between different treatments.
Outcome measures and data extraction
The following data were extracted from eligible studies
and shown in Table 1: gender, sample size and diagnostic
criteria. Two investigators reviewed the manuscripts of all
included studies and extracted data into a database inde-
pendently. A Jadad scale was generated and is presented
in Additional file 1: Table S1. The width of the lines in
Fig. 2 is proportional to the number of trials comparing
each pair of treatments and the area of circles represents
the cumulative number of patients for each intervention.
Statistical analysis
We initially carried out a conventional pair-wise meta-
analysis which directly compares each pair of treat-
ments. The corresponding odds ratios (ORs) and 95%
confidence intervals (CIs) for each study were pooled in
order to obtain the overall effect size. Furthermore, a
NMA was performed for each endpoint with a Bayesian
framework using R 3.2.3 software. Treatment efficacy
was compared through direct and indirect evidence
2,967 records identified
 through database searching
3 additional references 
from reviewers found
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Fig. 1 Study flow diagram
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Table 1 Included studies
Study information Blinding Number Female Diagnostic criteria Outcomes
Sumatriptan vs Placebo
Barbanti, 2004, Multinational Double 432 358 IHS ③
Bigal, 2015, USA Double 354 386 ICHD-II ③④
Bousser, 1993, France Double 96 79 IHS ③④⑤⑥⑧
Cady, 1998, USA Double 132 112 IHS ④⑥⑦⑧
Cady, 2015, USA Double 212 177 ICHD-II ③④⑤⑥
Diamond, 1998, USA Double 1077 956 IHS ②④⑤
Diener, 1999, Germany Double 156 125 IHS ③④⑥⑦⑧⑨
Djupesland, 2010, UK Double 78 71 IHS ②③④⑥⑧
Fujita, 2014, Japan Double 144 84 ICHD-II ①②③④⑧⑨
Goldstein, 2005, USA Double 104 - IHS ⑥⑦
Gross, 1994, UK Double 86 69 IHS ②⑥
Henry, 1993, France Double 76 66 IHS ①②③④⑥⑧
Jelinski, 2006, USA Double 235 308 IHS ①③⑨
Landy, 2004, UK Double 449 448 IHS ③⑨
Lipton, 2000, USA Double 1112 215 IHS ③④
Myllyla, 1998, Finland Double 94 84 IHS ③④⑤⑥⑦
Nappi, 1994, Italy Double 244 155 IHS ③④⑤⑥⑦⑧⑨
Peikert, 1999, Multinational Double 586 408 IHS ②③④⑧
Pini, 1995, Italy Double 240 - IHS ④⑥⑦⑧
Rao, 2016, USA Double 100 54 IHS ③④⑤⑨
Salonen, 1994, Multinational Double 247 30 IHS ②④
Schulman, 2000, USA Double 116 105 IHS ⑥⑦⑧
Sheftell, 2005, USA Double 904 1170 IHS ③⑥⑦⑨
Tfelt-Hansen, 1995, Multinational Double 248 192 IHS ④⑤⑥⑧⑨
Tfelt-Hansen, 2006, Denmark Double 100 78 - ③⑧
Wang, 2007, Taipei Double 56 48 - ①②③④⑦⑧⑨
Wendt, 2006, USA Double 577 500 - ①②③④⑥⑧⑨
Winner, 2003, USA Double 354 311 - ①③⑨
Winner, 2006, USA Double 297 246 - ③④⑥⑨
Zolmitriptan vs Placebo
Charlesworth, 2003, UK Double 1372 1138 IHS ⑥⑦⑧
Dahlof, 1998, Multinational Double 840 701 IHS ③④⑤⑥⑦⑧
Dodick, 2005, USA Double 1868 1620 IHS ①②③④⑤⑥⑦⑨
Dowson, 2002, Multinational Double 470 409 IHS ④⑥⑦⑧
Gawel, 2005, Canada Double 912 798 IHS ①②③④⑥⑧⑨
Klapper, 2004, UK Double 280 241 IHS ③⑥⑧⑨
Loder, 2005, USA Double 565 482 IHS ①③⑧⑨
Rothner, 2006, USA Double 346 410 IHS ①②③④⑧⑨
Ryan Jr, 2000, North America Double 734 628 IHS ①②③④⑥⑦
Sakai, 2002, Japan Double 202 150 IHS ②③④⑤⑧
Spierings, 2004, USA Double 670 580 IHS ①②③④⑤⑧⑨
Tepper, 1999, Multinational Double 1643 1387 IHS ③⑧
Tuchman, 2006, USA Double 336 - -
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Table 1 Included studies (Continued)
Almotriptan vs Placebo
Diener, 2005, Germany Double 221 192 IHS ③④⑧
Dowson, 2002, Multinational Double 470 409 IHS ④⑥⑦⑧
Mathew, 2007, USA Double 317 275 IHS ①②③④⑧⑨
Pascual, 2000, Multinational Double 909 788 IHS ①②③④⑤⑦⑧
Rizatriptan vs Placebo
Ahrens, 1999, USA Double 555 391 IHS ②③④⑤⑦⑨
Freitag, 2008, USA Double 82 72 IHS ③④⑤⑨
Mannix, 2007, USA Double 359 355 IHS ④⑤⑥⑧
Teall, 1998, Multinational Double 762 653 IHS ②④⑦⑧⑨
Misra, 2007, India Double 103 76 IHS ③④⑥⑧
Ibuprofen vs Placebo
Codispoti, 2001, USA Double 660 556 IHS ③④⑤⑧⑨
Goldstein, 2006, USA Double 886 722 IHS ④⑨
Kellstein, 2000, USA Double 729 550 IHS ③④⑤⑥
Misra, 2004, India Double 105 57 - ④
Sumatriptan-Naproxen vs Placebo
Mannix, 2009, USA Double 314 313 - ③⑥⑨
Martin, 2014, USA Double 623 622 ICHD-II
Silberstein, 2014, USA Double 443 331 ICHD-II ①②③⑤⑥⑧⑨
Winner, 2015, USA Double 349 66 ICHD ③
Eletriptan vs Placebo
Diener, 2002, Multinational Double 530 465 IHS ②③④⑨
Diclofenacpotassium vs Placebo
Comoglu, 2011, Turkey Double 45 10 IHS ②
Diener, 2006, Germany Double 590 762 IHS ③④⑥⑦⑨
Lipton, 2010, USA Double 690 585 IHS ③⑦⑧
Aspirin vs Placebo
Lange, 2000, Germany Double 345 - IHS ③④⑤⑥⑧
Lipton, 2005, USA Double 401 317 IHS ③④⑥⑦⑧⑨
Sumatriptan vs Zolmitriptan
Gallagher, 2000, USA Double 1212 1062 IHS ②④⑥⑦⑧⑨
Gruffyd-Jones, 2001, UK Double 1522 1299 IHS ①②③④⑥⑦⑧
Sumatriptan vs Almotriptan
Spierings, 2001, USA Double 1175 - IHS ②③④⑤⑥⑦⑧⑨
Sumatriptan vs Naratriptan
Gobel, 2000, Multinational Double 247 127 IHS ⑥⑦⑧⑨
Zolmitriptan vs Almotriptan
Goadsby, 2007, Italy Double 1062 902 - ③④⑥⑦⑨
Sumatriptan vs Zolmitriptan vs Placebo
Geraud, 2000, Multinational Double 558 472 - ①②③④⑥⑦⑧⑨
Sumatriptan vs Almotriptan vs Placebo
Dodick, 2002, Multinational Double 292 249 IHS ③⑥
Dowson, 2004, UK Double 295 - IHS ③⑧
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using the ORs and 95% credible intervals (CrIs). Then the
surface under curve ranking area (SUCRA) was created to
rank those interventions. The ranking probabilities were
defined as cumulative probabilities with each intervention
being ranked. For each endpoint, an intervention is more
desirable than others with a larger SUCRA value.
Results
Trial eligibility
We included double-blind RCTs to investigate the treat-
ment effects of triptans and NASIDs for adults according
to the International Classification of Headache Disorders
(ICHD), ICHD-II or the International Headache Society
(IHS) criteria.
Characteristic of included studies
All studies included were double-blind RCTs involving 1
four-arm trials with 287 participants and 17 three-arm
trials with 9,085 participants in all. The remaining 70
studies were two-arm trials that involve 13 comparisons
and a total of 34,850 participants. A detailed list of in-
cluded studies, patients and diagnostic criteria charac-
teristics is provided in Table 1. All included studies
were published between 1993 and 2016.
Pairwise comparisons
We completed pairwise meta-analysis for the 25 compari-
sons and the weighted ORs for each comparison were
calculated. The results of the pair-wise comparisons are
shown in Table 2 which illustrates the results of compari-
son of all 25 direct two-arm trials.
There were a total of 39,004 participants in the pla-
cebo controlled trials Direct placebo comparison results
suggest all treatments are more effective than placebo
with statistical significance in regards to 2 h-pain-free
and 2 h-pain-relief (OR > 1, 95% CI excludes 1). All
except diclofenac-potassium and almotriptan perform
use of rescue medication and most drugs examined
show efficacy in 1 h-pain-free and 1 h-pain-relief.
Sumatriptan, zolmitriptan, rizatriptan, naratriptan and
Table 1 Included studies (Continued)
Sumatriptan vs Rizatriptan vs Placebo
Goldstein, 1998, USA Double 441 - IHS ①②③④⑤⑦⑧⑨
Kolodny, 2004, USA Double 1104 - IHS ③⑧⑨
Tfelt-Hansen, 1998, Multinational Double 548 441 IHS ①②③④⑤⑥⑦⑧⑨
Sumatriptan vs Naratriptan vs Placebo
Dahlof, 1998, Multinational Double 840 701 IHS ③④⑤⑥⑦⑧
Havanka, 2000, Multinational Double 189 168 IHS ②④⑤⑥⑦⑧
Sumatriptan vs Sumatriptan-Naproxen vs Placebo
Brandes, 2007, USA Double 721 613 - ③④⑤⑥⑦⑨
Smith, 2005, Germany Double 471 422 IHS ①②③④⑤⑥⑦⑨
Sumatriptan vs Eletriptan vs Placebo
Mathew, 2003, Multinational Double 1250 1079 IHS ①②③④⑤⑥⑦⑧
Sumatriptan vs Diclofenacpotassium vs Placebo
DK/SMSG, 1999, Multinational Double 220 - IHS ⑤⑦⑧⑨
Sumatriptan vs Aspirin vs Placebo
Diener, 2004, Multinational Double 287 238 IHS ③④⑤⑥⑦⑧
Zolmitriptan vs Rizatriptan vs Placebo
Pascual, 2000, Multinational Double 909 788 IHS ①②③④⑤⑦⑧
Zolmitriptan vs Eletriptan vs Placebo
Steiner, 2003, Multinational Double 549 460 IHS ①②③④⑤⑦⑧
Rizatriptan vs Naratriptan vs Placebo
Bomhof, 1999, Multinational Double 308 262 IHS ①②③④⑤⑦⑧⑨
Rizatriptan vs Ibuprofen vs Placebo
Misra, 2007, India Double 103 76 IHS ③④⑥⑧
Sumatriptan vs Ibuprofen vs Aspirin vs Placebo
Diener, 2004, Multinational Double 287 238 IHS ③④⑤⑥⑦⑧
① 1 h pain free;② 1 h pain relief;③ 2 h pain free;④ 2 h pain relief;⑤ 2 h absence of nausea;⑥ rescue mediaction;⑦ recurrence;⑧ all-adverse events;⑨ nausea
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aspirin also show an increase in all-adverse events indi-
cating some side effects.
From pairwise meta-analysis between different medica-
tions, rizatriptan is more efficacious than naratriptan
concerning 1 h-pain-free, 2 h-pain-free and 2 h-pain-re-
lief (OR < 1, 95% CI excludes 1). However, naratriptan
manifests a lower recurrence than rizatriptan. Sumatrip-
tan has a worse performance than sumatriptan-naproxen
and eletriptan with respect to 2 h-pain-free and use of
rescue medication. We can derive that rizatriptan and
eletriptan tend to show effective performance with re-
spect to outcomes including 1 h-pain-relief and rescue
medication. However, a pairwise meta-analysis provides
limited information and does not enable us to synthesize
indirect evidence. Therefore we subsequently carried a
NMA for further information so that all treatments
could be compared and ranked.
Network meta-analysis
As suggested in Table 3 and Fig. 3, a large number of com-
parisons were generated by the NMA. As for 1 h-pain-
free, all medication except almotriptan and naratriptan
show statistical difference over placebo (Additional file 2:
Figure S1). Furthermore, zolmitriptan appears to be less
effective than rizatriptan and eletriptan, while other com-
parisons show no significant statistical difference. Like-
wise, results from NMA with respect to 1 h-pain-relief,
only sumatriptan, zolmitriptan, rizatriptan and eletriptan
show efficacy when compared with placebo but there were
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Fig. 2 Network of randomized controlled trials comparing different medications agents of migraine treatments. The width of the lines is proportional
to the number of trials comparing each pair of treatments; the area of circles represents the cumulative number of patients for each intervention
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For 2 h-pain-free, eletriptan shows efficacy over suma-
triptan, zolmitriptan, almotriptan, ibuprofen and aspirin,
while rizatriptan is more effective than sumatriptan, zolmi-
triptan, almotriptan, ibuprofen and aspirin but again there
is no statistical evidence to determine the efficacy contrast
between rizatriptan and eletriptan (Additional file 3:
Figure S2).
Diclofenac-potassium appears to be more effective
than any other intervention regarding 2 h-pain-relief.
Apart from that, eletriptan also shows promising re-
sults compared with sumatriptan, rizatriptan, ibuprofen
and aspirin. On the other hand, aspirin is less effective
than rizatriptan, naratriptan, sumatriptan-naproxen,
eletriptan and diclofenac-potassium. As a traditional
treatment, aspirin is regarded as low performance in re-
spect to 2 h-pain-relief, while diclofenac-potassium and
eletriptan are outstanding treatments concerning this
clinical outcome, and would be promising candidates in
acute therapies.
When analyzing 2 h-nausea-absence, rizatriptan has
better efficacy than sumatriptan while other treatments
except Sumatriptan-Naproxen indicate no distinctive dif-
ference even compared with placebo.
Sumatriptan, diclofenac-potassium and rizatriptan
present a much higher rate of recurrence figure compared
with naratriptan and sumatriptan-naproxen. Furthermore,
solid proof was obtained from the comparison between
mono-sumatriptan and sumatriptan-naproxen that na-
proxen significantly reduces the migraine recurrence rate
of sumatriptan while the efficacy of sumatriptan is barely
influenced, and further experiments could be designed to
investigate this mechanism and to combine treatments
with a view to improve their preventive abilities.
Rescue medication data demonstrated that diclofenac-
potassium performs the worst compared with rizatriptan,
ibuprofen, sumatriptan-naproxen and eletriptan, thus
diclofenac-potassium has the most likelihood of all treat-
ments to require a rescue medication. Considering that
naproxen has a notable promotion on the tolerability of
sumatriptan and that diclofenac-potassium has outstand-
ing behaviors with respect to efficacy, it is desirable to
design further experiments to enhance the tolerability of
diclofenac-potassium (Additional file 4: Figure S3).
Similarly, sumatriptan demonstrates a high all-adverse-
event behavior compared with diclofenac-potassium, ibu-
profen and almotriptan. Likewise naratriptan also has a
poor all-adverse-event perform when compared with
ibuprofen and diclofenac-potassium. In other words,
diclofenac-potassium and ibuprofen are milder when
compared with naratriptan and sumatriptan, which may
OR (95% CrI)Compared with Pacebo
Sumatriptan 3.50 (2.60, 5.00)
Zolmitriptan 2.90 (2.20, 3.90)
Almotriptan 2.20 (0.77, 6.60)
Rizatriptan 5.10 (3.20, 8.30)
Naratriptan 1.80 (0.50, 6.10)
Ibuprofen 5.40 (2.00, 14.0)
Sumatriptan-Naproxen 3.70 (1.80, 8.10)
Eletriptan 6.20 (3.40, 13.0)
Aspirin 3.30 (1.10, 9.10)
1 025.0

















































































































































































OR (95% CrI)Compared with Pacebo
Fig. 3 Odds ratios (95% credential intervals) for network comparison of migraine treatments
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indicate that NASIDs offer treatments with less adverse
reactions. Aside from this, the combination of sumatriptan
and naproxen appears to provide patients with much
better tolerance in comparison to sumatriptan alone.
With respect to nausea, zolmitriptan and sumatriptan
were significantly inferior to ibuprofen, sumatriptan-
naproxen, eletriptan and diclofenac-potassium. Interest-
ingly, eletriptan performs better than several other trip-
tans (Additional file 5: Figure S4).
Finally, Fig. 4 provides the ranking diagrams showing
probability of each strategy ranked (1–11) for outcomes
and Table 4 provides SUCRA results for further com-
parison. In general, NASIDs show a more prominent
tolerability while some triptans such as rizatriptan and
eletriptan exhibit more promising efficacy results. On
the other hand, almotriptan has the least effectiveness
with respect to 1 h-pain-free and 2 h-pain-free. Similar
rankings are displayed in Table 3, which reveals that
diclofenac-potassium and eletriptan has the best effi-
cacy whereas naratriptan and almotriptan are the least
efficacious medications.
Discussion
In this NMA, 10 medications were included and the re-
sult reveals that eletriptan offers the best efficacy and
acceptable tolerability. Besides, our research indicates
that ibuprofen exhibited the most desirable tolerability.
Furthermore, diclofenac-potassium and sumatriptan-
naproxen also showed favorable properties concerning
efficacy and tolerability.
Triptans were a group of 5-HT1B/1D agonists [102],
three main mechanisms of them were all conduced to
anti-migraine function. Firstly, triptans attenuated the
release of vasoactive peptides trigeminal system, as well
as reduced the migraine vascular inflammation. Moreover,



























































































































































































































Fig. 4 Probability of each medication with specific rank (1–11) for outcomes. Ranking indicates the probability to be the best treatment, the second
best and so on. Rank 1st is best and Rank 11th is worst
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pathway of central sensitization, thus helped to relieve the
pain from migraine [103, 104].
Considering the primary efficacy end-point, triptans
perform equally well compared to NSAIDs though ele-
triptan has the best efficacy, which lends credence to the
findings of Chris Cameron et al.’s 2015 study in principle
[105]. However, this study did not take adverse events
into account. Therefore, we apply 4 adverse-events to
characterize this ability in all 10 medications. Addition-
ally we also included a double-component therapy. Here
we report this NMA, revealing both the efficacy and the
tolerability of present medication against migraine.
At first, we focused on the differences apparent in the
primary efficacy end-point between different types of med-
ications. Rizatriptan provides relatively good freedom from
pain and nausea though with poor pain relief, the reason
for that might be the different criteria for efficacy in each
study. When it comes to tolerability, NASIDs seem to be
more attractive solutions. Also, it is of significance that
this study found naproxen is capable of significantly im-
proving the tolerability of sumatriptan and has no influ-
ence on its efficacy.
As suggested by the rank probability of SUCRA, ele-
triptan exhibited the most considerable efficacy. From
the SUCRA data, it is obvious that eletriptan can reduce
pain with a better result than any other medication. In
the meantime it also performs better than most of others
in 1 h pain-free and 2 h pain-free. Eletriptan is a new 5-
HT1B/1D/1F-selective receptor agonist with a higher affin-
ity to the receptors when compared with other triptans
[106]. Besides, more rapid and consistent absorption has
been achieved through structural design, and this has
made it possible for the drug to pass through the blood-
brain barrier [107]. As a result of its enhanced hydro-
phobility, higher bioavailability and longer plasma half-
life have also been reported [108]. When compared with
sumatriptan and other triptans, the difference in efficacy
may be explained by the overcoming of the blood-brain
barrier, which leads to a faster and more consistent ab-
sorption [107].
When we turn attention to the NSAIDs, ibuprofen
attracted us by its superior tolerability amongst all ob-
served medications. Though ibuprofen has been available
as a non-prescription medication for more than 40 years,
the mechanism of how the drug works is still not com-
pletely understood. According to a widely accepted theory,
it may be related to prostaglandin synthetase inhibition,
therefore allowing better tolerability. From the SUCRA
data we can observe that ibuprofen ranked top three in all
the adverse-event indications.
The results of SUCRA also showed that the diclopenac
potassium performs with high efficacy and tolerability, in
fact it stood the best option among NSAIDs from a com-
prehensive point of view. At the mechanism level,
NSAIDs inhibit the activity of cyclooxygenase (COX),
which is recognized as being composed of two isoforms
(COX-1& COX-2). COX acts as a catalyst during the pro-
duction for prostaglandins, a substance responsible for
pain and inflammation. Diclofenac inhibit both COX iso-
forms, though with a lower activity for COX-2 [109, 110].
Meanwhile we recognized that sumatriptan-naproxen
also offered a high-level tolerability, ranking first in
rescue medication and recurrence and fourth in the
other two indications among the ten medications. The
addition of naproxen significantly improved the toler-
ability of sumatriptan. To understand the reason for
this we referred to the mechanism of both the medi-
cines and the migraine.
The pathophysiology mechanism of migraine is quite
complex, involving multiple neural pathways that appear
to be pivotal during the process [111]. In the early stage
of a migraine, vasoactive and substances including calci-
tonin gene-related peptide and kinins are released by
trigeminal nerve endings under the stimulation of
















Placebo 0.024 0.045 0.000 0.000 0.178 0.092 0.602 0.782 0.561
Sumatriptan 0.490 0.483 0.602 0.318 0.376 0.418 0.280 0.189 0.165
Zolmitriptan 0.343 0.476 0.460 0.909 0.418 - 0.457 0.294 0.095
Almotriptan 0.282 0.358 0.186 0.432 0.394 - 0.249 0.589 0.388
Rizatriptan 0.712 0.458 0.824 0.341 0.765 0.602 0.203 0.367 0.358
Naratriptan 0.208 0.344 0.397 0.409 0.467 0.337 0.808 0.137 0.569
Ibuprofen 0.716 0.558 0.356 0.455 0.385 0.678 0.662 0.711 0.715
Sumatriptan-Naproxen 0.493 0.354 0.537 0.523 0.719 0.706 0.801 0.452 0.476
Eletriptan 0.783 0.664 0.874 0.636 0.455 0.689 0.322 0.587 0.880
Diclofenacpotassium - 0.642 0.504 0.818 0.516 0.040 0.190 0.743 0.705
Aspirin 0.452 0.608 0.262 0.159 0.342 0.417 0.429 0.133 0.103
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cortical spreading depression. At the same time, the cen-
tral pathways’ activation depends on the signals of pain
from the periphery. However, in the later stage, central
sensitization has no relationship with peripheral neural
input [112].
Considering the multiple pathogenic mechanisms,
multi-mechanism-targeted therapy may have better ef-
fect than monotherapy. Triptans not only decrease
transmission of the pain impulses to the trigeminal nu-
cleus caudalis but also release inflammatory mediators
from trigeminal nerves, therefore reduce calcitonin
gene-related peptide-mediated vasodilation [113]. As
for naproxen, it suppressed sensitization of central trige-
minovascular neurons in the spinal trigeminal nucleus
[20]. In our study, the combination of sumatriptan and na-
proxen effectively altered peripheral activation of central
pathways during early period and development of central
sensitization during later periods. As a result, a high-level
tolerability was observed, and this possibility was sup-
ported by several clinical studies [114–116].
What attracted our attention most is the potentiality
to combine different medications together and make use
of the advantages of each considering the relevant stage.
Applying different medications to intervene at every key
point of the multiple pathogenic mechanisms may bring
us closer to a better outcome. For instance, we may
combine naproxen with eletriptan to attain treatments
with both optimal efficacy and tolerability.
As with all analyses, we still cannot avoid several limita-
tions. First, age and gender was not under consideration.
Further research is needed in assessing the efficacy for dif-
ferent groups of people. Second, long-term assessment is
also important. As we all know, people who suffer from
migraine may undergo a long-period treatment and there-
fore the efficacy and safety of medications are vital. Third,
the dosage of medications was not considered and that
may cause some deviations.
Conclusions
In conclusion, through this NMA we came to the inter-
pretation that eletriptan may be the most suitable therapy
for migraine from a comprehensive point of view. In the
meantime ibuprofen may also be a good choice for its
excellent tolerability. Multi-component medication also
attracted our attention and it may be a promising orienta-
tion for the next generation of medication for migraine.
Article highlights
1. Uses NMA to analysis the efficacy and tolerability of
NSAIDs and triptans in migraine.
2. Eletriptan may be the most preferable treatment for
migraine from a comprehensive point of view.
3. Ibuprofen has the best tolerability among all the
medications.
4. Multi-component medication may be a good choice
for the migraine medication in the future.
Additional files
Additional file 1: Table S1. Jadad scale table of 88 included studies
(DOCX 20 kb)
Additional file 2: Figure S1. Node splitting of direct and indirect
comparisons according to type of interventions for 1 h clinical outcomes.
(EPS 1868 kb)
Additional file 3: Figure S2. Node splitting of direct and indirect
comparisons according to type of interventions for 2 h clinical outcomes.
(EPS 2444 kb)
Additional file 4: Figure S3. Node splitting of direct and indirect
comparisons according to type of interventions for rescue medication
and recurrence. (EPS 1963 kb)
Additional file 5: Figure S4. Node splitting of direct and indirect
comparisons according to type of interventions for all adverse events.
Treatment: A Placebo; B Sumatriptan; C Zolmitriptan; D Almotriptan; E
Rizatriptan; F Naratriptan; G Ibuprofen; H Sumatriptan-Naproxen; I




HX and ML were involved in conception and design of the study. WH
collected, analyzed, and interpreted the data. The manuscript was drafted by
HX and JW. All authors reviewed and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 16 October 2016 Accepted: 28 November 2016
References
1. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of
migraine headache in the United States. Relation to age, income, race, and
other sociodemographic factors. JAMA 267(1):64–69
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence
and burden of migraine in the United States: data from the American
Migraine Study II. Headache 41(7):646–657
3. Gobel H, Petersen-Braun M, Soyka D (1994) The epidemiology of headache in
Germany: a nationwide survey of a representative sample on the basis of the
headache classification of the International Headache Society. Cephalalgia
14(2):97–106
4. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R (1992) A
nationwide survey of migraine in France: prevalence and clinical features in
adults. GRIM. Cephalalgia 12(4):229–237, discussion 186
5. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A (2016) Recent advances in
migraine therapy. Springerplus 5:637
6. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012)
Evidence-based guideline update: pharmacologic treatment for episodic
migraine prevention in adults: report of the Quality Standards
Subcommittee of the American Academy of Neurology and the American
Headache Society. Neurology 78(17):1337–1345
Xu et al. The Journal of Headache and Pain  (2016) 17:113 Page 15 of 18
7. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS
guideline on the drug treatment of migraine–revised report of an EFNS task
force. Eur J Neurol 16(9):968–981
8. Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of
migraine in adults: the american headache society evidence assessment of
migraine pharmacotherapies. Headache 55(1):3–20
9. Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S (2016)
How to apply the AHS evidence assessment of the acute treatment of
migraine in adults to your patient with migraine. Headache 56(7):1194–1200
10. Diamond ML, Hettiarachchi J, Hilliard B, Sands G, Nett R (2004) Effectiveness
of eletriptan in acute migraine: primary care for Excedrin nonresponders.
Headache 44(3):209–216
11. Pascual J, Cabarrocas X (2002) Within-patient early versus delayed
treatment of migraine attacks with almotriptan: the sooner the better.
Headache 42(1):28–31
12. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2004) Almotriptan
improves response rates when treatment is within 1 hour of migraine
onset. Headache 44(4):318–322
13. Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with
triptans: a race against the development of cutaneous allodynia. Ann
Neurol 55(1):19–26
14. Linde M, Mellberg A, Dahlof C (2006) Subcutaneous sumatriptan provides
symptomatic relief at any pain intensity or time during the migraine attack.
Cephalalgia 26(2):113–121
15. (1999) Acute treatment of migraine attacks: efficacy and safety of a
nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison
to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine
Study Group. Cephalalgia 19(4):232–240
16. Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA et al
(1999) Efficacy and safety of rizatriptan wafer for the acute treatment of
migraine. Cephalalgia 19(5):525–530
17. Barbanti P, Carpay JA, Kwong WJ, Ahmad F, Boswell D (2004) Effects of a fast
disintegrating/rapid release oral formulation of sumatriptan on functional
ability in patients with migraine. Curr Med Res Opin 20(12):2021–2029
18. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K (1999) Comparison of
rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 42(3):173–179
19. Bousser MG, D’Allens H, Richard A (1993) Efficacy of subcutaneous
sumatriptan in the acute treatment of early-morning migraine: a placebo-
controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern
Med 234(2):211–216
20. Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ et al
(2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized
trial. JAMA 297(13):1443–1454
21. Bussone G, Manzoni GC, Cortelli P, Roncolato M, Fabbri L, Benassuti C (2000)
Efficacy and tolerability of sumatriptan in the treatment of multiple
migraine attacks. Neurol Sci 21(5):272–278
22. Cady RC, Ryan R, Jhingran P, O’Quinn S, Pait DG (1998) Sumatriptan
injection reduces productivity loss during a migraine attack: results of a
double-blind, placebo-controlled trial. Arch Intern Med 158(9):1013–1018
23. Carleton SC, Shesser RF, Pietrzak MP, Chudnofsky CR, Starkman S, Morris DL
et al (1998) Double-blind, multicenter trial to compare the efficacy of
intramuscular dihydroergotamine plus hydroxyzine versus intramuscular
meperidine plus hydroxyzine for the emergency department treatment of
acute migraine headache. Ann Emerg Med 32(2):129–138
24. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M
(2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute
treatment of migraine: a randomised, double-blind, placebo-controlled,
dose-ranging study versus zolmitriptan tablet. CNS Drugs 17(9):653–667
25. Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB (2001) Efficacy of
nonprescription doses of ibuprofen for treating migraine headache. A
randomized controlled trial. Headache 41(7):665–679
26. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J et al
(1998) Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral
treatment of migraine: a multicentre, dose-range finding study. Eur J
Neurol 5(6):535–543
27. Dahlof C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al (1998)
Early clinical experience with subcutaneous naratriptan in the acute
treatment of migraine: a dose-ranging study. Eur J Neurol 5(5):469–477
28. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M (1998)
Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the
treatment of migraine. Arch Fam Med 7(3):234–240
29. Diener HC (1999) Efficacy and safety of intravenous acetylsalicylic acid
lysinate compared to subcutaneous sumatriptan and parenteral placebo in
the acute treatment of migraine. A double-blind, double-dummy,
randomized, multicenter, parallel group study. The ASASUMAMIG Study
Group. Cephalalgia 19(6):581–588, discussion 542
30. Diener HC, Bussone G, De Liano H, Eikermann A, Englert R, Floeter T et al
(2004) Placebo-controlled comparison of effervescent acetylsalicylic acid,
sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia
24(11):947–954
31. Diener HC, Eikermann A, Gessner U, Gobel H, Haag G, Lange R et al (2004)
Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in
treating associated migraine symptoms. Eur Neurol 52(1):50–56
32. Diener HC, Gendolla A, Gebert I, Beneke M (2005) Almotriptan in migraine
patients who respond poorly to oral sumatriptan: a double-blind,
randomized trial. Eur Neurol 53(Suppl 1):41–48
33. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002) Efficacy,
tolerability and safety of oral eletriptan and ergotamine plus caffeine
(Cafergot) in the acute treatment of migraine: a multicentre, randomised,
double-blind, placebo-controlled comparison. Eur Neurol 47(2):99–107
34. Diener HC, Montagna P, Gács G, Lyczak P, Schumann G, Zöller B et al (2006)
Efficacy and tolerability of diclofenac potassium sachets in migraine: a
randomized, double-blind, cross-over study in comparison with diclofenac
potassium tablets and placebo. Cephalalgia 26(5):537–547
35. Djupesland PG, Docekal P (2010) Intranasal sumatriptan powder delivered by a
novel breath-actuated bi-directional device for the acute treatment of
migraine: a randomised, placebo-controlled study. Cephalalgia 30(8):933–942
36. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L (2005) Speed of onset,
efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of
migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs
19(2):125–136
37. Dodick DW (2002) Almotriptan increases sustained pain-free outcomes in acute
migraine: results from three controlled clinical trials. Headache 42(1):21–27
38. Dowson A, Ball K, Haworth D (2000) Comparison of a fixed combination of
domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in
moderate to severe migraine: a randomised UK primary care study. Curr
Med Res Opin 16(3):190–197
39. Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL (2002)
Zolmitriptan orally disintegrating tablet is effective in the acute treatment
of migraine. Cephalalgia 22(2):101–106
40. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2002) Almotriptan is an
effective and well-tolerated treatment for migraine pain: results of a
randomized, double-blind, placebo-controlled clinical trial. Cephalalgia
22(6):453–461
41. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F
(2008) Efficacy and tolerability of coadministration of rizatriptan and
acetaminophen vs rizatriptan or acetaminophen alone for acute migraine
treatment. Headache 48(6):921–930
42. Gallagher RM, Dennish G, Spierings EL, Chitra R (2000) A comparative trial of
zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Headache 40(2):119–128
43. Gawel M, Aschoff J, May A, Charlesworth BR (2005) Zolmitriptan 5 mg nasal
spray: efficacy and onset of action in the acute treatment of migraine–
results from phase 1 of the REALIZE Study. Headache 45(1):7–16
44. Geraud G, Compagnon A, Rossi A (2002) Zolmitriptan versus a combination of
acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine:
a double-blind, randomised, three-attack study. Eur Neurol 47(2):88–98
45. Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC et
al (2000) Comparison of the efficacy of zolmitriptan and sumatriptan: issues
in migraine trial design. Cephalalgia 20(1):30–38
46. Goadsby PJ, Massiou H, Pascual J, Diener HC, Dahlof CG, Mateos V et al
(2007) Almotriptan and zolmitriptan in the acute treatment of migraine.
Acta Neurol Scand 115(1):34–40
47. Gobel H, Winter P, Boswell D, Crisp A, Becker W, Hauge T et al (2000) Comparison
of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan
International Recurrence Study Group. Clin Ther 22(8):981–989
48. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA et al (1998)
Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan
25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.
Headache 38(10):737–747
49. Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM et al
(2005) Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in
Xu et al. The Journal of Headache and Pain  (2016) 17:113 Page 16 of 18
the early treatment of migraine: results from the ASSET trial. Headache
45(8):973–982
50. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB (2006)
Acetaminophen, aspirin, and caffeine in combination versus ibuprofen
for acute migraine: results from a multicenter, double-blind, randomized,
parallel-group, single-dose, placebo-controlled study. Headache
46(3):444–453
51. Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H (1994) Sumatriptan
in acute migraine using a novel cartridge system self-injector. United
Kingdom Study Group. Headache 34(10):559–563
52. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Rosjo O, Millson DS (2001)
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a
randomized, double-blind, international study. Eur J Neurol 8(3):237–245
53. Havanka H, Dahlof C, Pop PH, Diener HC, Winter P, Whitehouse H et al
(2000) Efficacy of naratriptan tablets in the acute treatment of migraine:
a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther
22(8):970–980
54. Henry P, d’Allens H (1993) Subcutaneous sumatriptan in the acute
treatment of migraine in patients using dihydroergotamine as prophylaxis.
French Migraine Network Bordeaux-Lyon-Grenoble. Headache 33(8):432–435
55. Jelinski SE, Becker WJ, Christie SN, Ahmad FE, Pryse-Phillips W, Simpson SD
(2006) Pain free efficacy of sumatriptan in the early treatment of migraine.
Can J Neurol Sci 33(1):73–79
56. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF et al
(2000) Evaluation of a novel solubilized formulation of ibuprofen in the
treatment of migraine headache: a randomized, double-blind, placebo-
controlled, dose-ranging study. Cephalalgia 20(4):233–243
57. Klapper J, Lucas C, Rosjo O, Charlesworth B (2004) Benefits of treating highly
disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia
24(11):918–924
58. Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F (2004)
Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg
and 50 mg tablets. Cephalalgia 24(7):540–546
59. Lange R, Schwarz JA, Hohn M (2000) Acetylsalicylic acid effervescent
1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized,
double-blind, single-dose, placebo-controlled parallel group study.
Cephalalgia 20(7):663–667
60. Le Jeunne C, Gomez JP, Pradalier A, Titus i Albareda F, Joffroy A, Liano H et
al (1999) Comparative efficacy and safety of calcium carbasalate plus
metoclopramide versus ergotamine tartrate plus caffeine in the treatment
of acute migraine attacks. Eur Neurol 41(1):37–43
61. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S et al (2002)
Children’s ibuprofen suspension for the acute treatment of pediatric
migraine. Headache 42(8):780–786
62. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M (2000) Efficacy and
safety of acetaminophen in the treatment of migraine: results of a
randomized, double-blind, placebo-controlled, population-based study. Arch
Intern Med 160(22):3486–3492
63. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN
(2005) Aspirin is efficacious for the treatment of acute migraine. Headache
45(4):283–292
64. Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN et
al (2010) Efficacy and tolerability of a new powdered formulation of
diclofenac potassium for oral solution for the acute treatment of migraine:
results from the International Migraine Pain Assessment Clinical Trial
(IMPACT). Cephalalgia 30(11):1336–1345
65. Lipton RB, Stewart WF, Cady R, Hall C, O’Quinn S, Kuhn T et al (2000)
Sumatriptan for the range of headaches in migraine sufferers: results of the
spectrum study. Headache 40(10):783–791
66. Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S (2005) Pain-free
rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine:
results of a large double-blind placebo- controlled trial. Curr Med Res Opin
21(3):381–389
67. MacGregor EA, Dowson A, Davies PT (2002) Mouth-dispersible aspirin in the
treatment of migraine: a placebo-controlled study. Headache 42(4):249–255
68. Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM et al (2007)
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine:
two prospective, randomized, placebo-controlled, double-blind studies.
Cephalalgia 27(5):414–421
69. Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD et al (2009)
Combination treatment for menstrual migraine and dysmenorrhea using
sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol
114(1):106–113
70. Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L et al (2007)
Early intervention with almotriptan: results of the AEGIS trial (AXERT Early
Migraine Intervention Study). Headache 47(2):189–198
71. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR (2003)
Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.
Headache 43(3):214–222
72. Misra UK, Jose M, Kalita J (2004) Rofecoxib versus ibuprofen for acute
treatment of migrainne: a randomised placebo controlled trial. Postgrad
Med J 80(950):720–723
73. Misra UK, Kalita J, Yadav RK (2007) Rizatriptan vs. ibuprofen in migraine: a
randomised placebo-controlled trial. J Headache Pain 8(3):175–179
74. Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J et al
(1998) Tolfenamic acid rapid release versus sumatriptan in the acute
treatment of migraine: comparable effect in a double-blind, randomized,
controlled, parallel-group study. Headache 38(3):201–207
75. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O (1994) Oral
sumatriptan compared with placebo in the acute treatment of migraine.
J Neurol 241(3):138–144
76. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M et al (2000)
Consistent efficacy and tolerability of almotriptan in the acute treatment of
multiple migraine attacks: results of a large, randomized, double-blind,
placebo-controlled study. Cephalalgia 20(6):588–596
77. Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K (2000)
Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the
acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.
Cephalalgia 20(5):455–461
78. Peikert A, Becker WJ, Ashford EA, Dahlof C, Hassani H, Salonen RJ (1999)
Sumatriptan nasal spray: a dose-ranging study in the acute treatment of
migraine. Eur J Neurol 6(1):43–49
79. Peroutka SJ, Lyon JA, Swarbrick J, Lipton RB, Kolodner K, Goldstein J (2004)
Efficacy of diclofenac sodium softgel 100 mg with or without caffeine
100 mg in migraine without aura: a randomized, double-blind, crossover
study. Headache 44(2):136–141
80. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of
sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of
migraine: defining the optimum doses of oral sumatriptan. Headache 38(3):
184–190
81. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J (2006)
Zolmitriptan oral tablet in migraine treatment: high placebo responses in
adolescents. Headache 46(1):101–109
82. Ryan RE Jr, Diamond S, Giammarco RAM, Aurora SK, Reed RC, Fletcher PE
(2000) Efficacy of Zolmitriptan at early time-points for the acute treatment
of migraine and treatment of recurrence: a randomised, placebo-controlled
trial. CNS Drugs 13(3):215–226
83. Sakai F, Iwata M, Tashiro K, Itoyama Y, Tsuji S, Fukuuchi Y et al (2002)
Zolmitriptan is effective and well tolerated in Japanese patients with
migraine: a dose–response study. Cephalalgia 22(5):376–383
84. Salonen R, Ashford E, Dahlof C, Dawson R, Gilhus NE, Luben V et al (1994)
Intranasal sumatriptan for the acute treatment of migraine. International
Intranasal Sumatriptan Study Group. J Neurol 241(8):463–469
85. Scherl ER, Wilson JF (1995) Comparison of dihydroergotamine with
metoclopramide versus meperidine with promethazine in the treatment of
acute migraine. Headache 35(5):256–259
86. Schulman EA, Cady RK, Henry D, Batenhorst AS, Putnam DG, Watson CB et
al (2000) Effectiveness of sumatriptan in reducing productivity loss due to
migraine: results of a randomized, double-blind, placebo-controlled clinical
trial. Mayo Clin Proc 75(8):782–789
87. Schulman EA, Dermott KF (2003) Sumatriptan plus metoclopramide in
triptan-nonresponsive migraineurs. Headache 43(7):729–733
88. Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS (2005)
Two replicate randomized, double-blind, placebo-controlled trials of the
time to onset of pain relief in the acute treatment of migraine with a fast-
disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther
27(4):407–417
89. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ (2005)
Sumatriptan and naproxen sodium for the acute treatment of migraine.
Headache 45(8):983–991
90. Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens
KJ (2001) Oral almotriptan vs. oral sumatriptan in the abortive treatment of
Xu et al. The Journal of Headache and Pain  (2016) 17:113 Page 17 of 18
migraine: a double-blind, randomized, parallel-group, optimum-dose
comparison. Arch Neurol 58(6):944–950
91. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B (2004) Acute
treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet.
CNS Drugs 18(15):1133–1141
92. Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR
(2003) Comparative efficacy of eletriptan and zolmitriptan in the acute
treatment of migraine. Cephalalgia 23(10):942–952
93. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B et al (1998)
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine
recurrence. A placebo-controlled, outpatient study. Headache 38(4):281–287
94. Tepper SJ, Donnan GA, Dowson AJ, Bomhof MA, Elkind A, Meloche J et al
(1999) A long-term study to maximise migraine relief with zolmitriptan. Curr
Med Res Opin 15(4):254–271
95. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G
(1995) The effectiveness of combined oral lysine acetylsalicylate and
metoclopramide compared with oral sumatriptan for migraine. Lancet
346(8980):923–926
96. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W et al
(1998) Oral rizatriptan versus oral sumatriptan: a direct comparative study in
the acute treatment of migraine. Rizatriptan 030 Study Group. Headache
38(10):748–755
97. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A (1996) A comparison of
subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute
treatment of migraine. Neurology 47(2):361–365
98. Tullo V, Allais G, Ferrari MD, Curone M, Mea E, Omboni S et al (2010)
Frovatriptan versus zolmitriptan for the acute treatment of migraine:
a double-blind, randomized, multicenter, Italian study. Neurol Sci 31
(Suppl 1):S51–S54
99. Wang SJ, Fuh JL, Wu ZA (2007) Intranasal sumatriptan study with high
placebo response in Taiwanese patients with migraine. J Chin Med Assoc
70(2):39–46
100. Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S et al (2006) A
randomized, double-blind, placebo-controlled trial of the efficacy and
tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment
of acute migraine attacks in adults. Clin Ther 28(4):517–526
101. Winner P, Mannix LK, Putnam DG, McNeal S, Kwong J, O’Quinn S et al
(2003) Pain-free results with sumatriptan taken at the first sign of migraine
pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin
Proc 78(10):1214–1222
102. Capi M, Curto M, Lionetto L, de Andres F, Gentile G, Negro A et al (2016)
Eletriptan in the management of acute migraine: an update on the
evidence for efficacy, safety, and consistent response. Ther Adv Neurol
Disord 9(5):414–423
103. Lionetto L, Casolla B, Mastropietri F, D’Alonzo L, Negro A, Simmaco M et al
(2012) Pharmacokinetic evaluation of zolmitriptan for the treatment of
migraines. Expert Opin Drug Metab Toxicol 8(8):1043–1050
104. Napoletano F, Lionetto L, Martelletti P (2014) Sumatriptan in clinical
practice: effectiveness in migraine and the problem of psychiatric
comorbidity. Expert Opin Pharmacother 15(3):303–305
105. Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al (2015)
Triptans in the acute treatment of migraine: a systematic review and
network meta-analysis. Headache 55(Suppl 4):221–235
106. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R (1999)
Characterisation of the 5-HT receptor binding profile of eletriptan and
kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Eur J Pharmacol 368(2–3):259–268
107. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L (2000)
Effects of eletriptan on the peptidergic innervation of the cerebral dura
mater and trigeminal ganglion, and on the expression of c-fos and c-jun in
the trigeminal complex of the rat in an experimental migraine model. Eur J
Neurosci 12(11):3991–4002
108. Johnson DE, Rollema H, Schmidt AW, McHarg AD (2001) Serotonergic
effects and extracellular brain levels of eletriptan, zolmitriptan and
sumatriptan in rat brain. Eur J Pharmacol 425(3):203–210
109. Patrono C, Patrignani P, Garcia Rodriguez LA (2001) Cyclooxygenase-
selective inhibition of prostanoid formation: transducing biochemical
selectivity into clinical read-outs. J Clin Invest 108(1):7–13
110. Patrono C, Baigent C (2009) Low-dose aspirin, coxibs, and other NSAIDS: a
clinical mosaic emerges. Mol Interv 9(1):31–39
111. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine–current understanding
and treatment. N Engl J Med 346(4):257–270
112. Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous
allodynia during a migraine attack clinical evidence for the sequential
recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain
123(Pt 8):1703–1709
113. Burstein R (2001) Deconstructing migraine headache into peripheral and
central sensitization. Pain 89(2–3):107–110
114. Loo CY, Tan HJ, Teh HS, Raymond AA (2007) Randomised, open label,
controlled trial of celecoxib in the treatment of acute migraine. Singapore
Med J 48(9):834–839
115. Krymchantowski AV, Bigal ME (2004) Rizatriptan versus rizatriptan plus
rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of
migraine. BMC Neurol 4:10
116. Krymchantowski AV, Barbosa JS (2002) Rizatriptan combined with rofecoxib
vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
Cephalalgia 22(4):309–312
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Xu et al. The Journal of Headache and Pain  (2016) 17:113 Page 18 of 18
